Pharmaceutical biotechnology : (Record no. 11818)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 05902cam a2200649Ia 4500 |
| 001 - CONTROL NUMBER | |
| control field | ocn784885298 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20171224113920.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS--GENERAL INFORMATION | |
| fixed length control field | m o d |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr |n|---||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 120409s2012 njua ob 001 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | EBLCP |
| Language of cataloging | eng |
| Description conventions | pn |
| Transcribing agency | EBLCP |
| Modifying agency | OCLCQ |
| -- | MHW |
| -- | DG1 |
| -- | YDXCP |
| -- | MYG |
| -- | OCLCQ |
| -- | HEBIS |
| -- | OCLCF |
| -- | OCLCA |
| -- | OCLCQ |
| -- | S3O |
| -- | OCLCQ |
| -- | DEBBG |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9783527632909 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 3527632905 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Cancelled/invalid ISBN | 9783527651252 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Cancelled/invalid ISBN | 352765125X |
| 029 1# - (OCLC) | |
| OCLC library identifier | AU@ |
| System control number | 000049569125 |
| 029 1# - (OCLC) | |
| OCLC library identifier | NZ1 |
| System control number | 15900693 |
| 029 1# - (OCLC) | |
| OCLC library identifier | DEBBG |
| System control number | BV043394438 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)784885298 |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RS380 |
| Item number | .P488 2012eb |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 615.1 |
| Edition number | 23 |
| 049 ## - LOCAL HOLDINGS (OCLC) | |
| Holding library | MAIN |
| 245 00 - TITLE STATEMENT | |
| Title | Pharmaceutical biotechnology : |
| Remainder of title | drug discovery and clinical applications. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 2nd rev. ed. / |
| Remainder of edition statement | edited by Oliver Kayser, Heribert Warzecha. |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
| Place of publication, distribution, etc | Hoboken : |
| Name of publisher, distributor, etc | John Wiley & Sons, |
| Date of publication, distribution, etc | 2012. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (xxvii, 647 pages) : |
| Other physical details | illustrations |
| 336 ## - | |
| -- | text |
| -- | txt |
| -- | rdacontent |
| 337 ## - | |
| -- | computer |
| -- | c |
| -- | rdamedia |
| 338 ## - | |
| -- | online resource |
| -- | cr |
| -- | rdacarrier |
| 500 ## - GENERAL NOTE | |
| General note | Previous edition: 2004. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc | Includes bibliographical references and index. |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover; Related Titles; Title page; Copyright page; Preface to the 2nd Edition; List of Contributors; Part One: Concepts and Methods for Recombinant Drug Production; 1 Pharmaceutical Biotechnology and Industrial Applications -- Learning Lessons from Molecular Biology; 1.1 Introduction; 1.2 Research Developments; 1.3 Production Hosts and Upstream/Downstream Processing; 1.4 Future Outlook; 2 Prokaryotic Cells in Biotech Production; 2.1 Introduction; 2.2 Production of Natural Products by Microorganisms; 2.3 Prokaryotes as Producers of Recombinant Therapeutic Proteins. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 3 Mammalian Cells in Biotech Production3.1 Introduction; 3.2 Process Concepts and Cells; 3.3 CHO-Derived Production Cell Lines; 3.4 Rapid Generation of High-Producing Cell Lines; 3.5 Silencing -- Stability of Expression; 3.6 High-Throughput Bioprocess Development; 3.7 Disposable Bioreactors; 3.8 Transient Gene Expression (TGE); 3.9 Conclusions; 4 Biopharmaceuticals from Plants; 4.1 Introduction; 4.2 Basics in Plant Biotechnology; 4.3 Plant Cell Cultures as Production System for Human Glucocerebrosidase; 4.4 Insulin from Safflower -- A Unique Purification Scheme. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 4.5 Fast and Scalable Transient Tobacco-Based Expression Systems4.6 Conclusion; 5 Production of Biopharmaceuticals in Transgenic Animals; 5.1 Introduction; 5.2 Sites of Production; 5.3 Transgenic Constructs; 5.4 Methods for the Production of Transgenic Animals; 5.5 Analysis of Transgenic Animals; 5.6 Quality and Safety of the Product; 5.7 Conclusions and Outlook; 6 Translation of New Technologies in Biomedicines: Shaping the Road from Basic Research to Drug Development and Clinical Application -- and Back Again; 6.1 Drug Discovery and Development; 6.2 The Nature of Models and the Need for Them. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 6.3 New Technologies Toolbox6.4 Strategic Use of the New Technology Tools; 6.5 Translation as a Two-Way Process; 6.6 Concluding Comment; Part Two: Bringing the Drug into Action -- From Downstreaming to Approval; 7 Overview and Classification of Approved Recombinant Drugs; 7.1 Introduction; 7.2 Classification of Recombinant Drugs from a Technical Point of View; 7.3 Expression Systems; 7.4 Proteins Derived from Modified Genes; 7.5 Artificial Proteins; 7.6 Post-expression Modifications of Recombinant Proteins; 7.7 Biosimilars; 8 Downstream Processing; 8.1 Introduction. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 8.2 General Principles of DSP8.3 Clarification; 8.4 Chromatography; 8.5 Ultrafiltration/Diafiltration, and Virus Filtration; 8.6 Crystallization; 8.7 Recent Developments in Downstream Processing; 9 Characterization of Recombinant Proteins; 9.1 Introduction; 9.2 Physical Chemical Characterization; 9.3 Biological Characterization of Biopharmaceuticals In Vitro; Acknowledgments; Legals; 10 Formulation Strategies for Recombinant Protein and Related Biotech Drugs; 10.1 Introduction; 10.2 Formulation and Stability of Protein Solutions; 10.3 Formulation of Vaccines. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 11 Drug Approval in the European Union and United States. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc | "This second edition of a very successful book is thoroughly updated with existing chapters completely rewritten while the content has more than doubled from 16 to 36 chapters. As with the first edition, the focus is on industrial pharmaceutical research, written by a team of industry experts from around the world, while quality and safety management, drug approval and regulation, patenting issues, and biotechnology fundamentals are also covered. In addition, this new edition now not only includes biotech drug development but also the use of biopharmaceuticals in diagnostics and vaccinations."--Provided by publisher. |
| 588 0# - | |
| -- | Print version record. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmaceutical biotechnology. |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmaceutical biotechnology. |
| Source of heading or term | fast |
| -- | (OCoLC)fst01060106 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Pharmazeutische Technologie |
| Source of heading or term | gnd |
| -- | (DE-588)4045699-7 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Biotechnologie |
| Source of heading or term | gnd |
| -- | (DE-588)4069491-4 |
| 650 #7 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name as entry element | Bioteknik. |
| Source of heading or term | sao |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Kayser, Oliver. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Warzecha, Heribert. |
| 710 2# - ADDED ENTRY--CORPORATE NAME | |
| Corporate name or jurisdiction name as entry element | Wiley InterScience (Online service) |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Display text | Print version: |
| Main entry heading | Kayser, Oliver. |
| Title | Pharmaceutical Biotechnology : Drug Discovery and Clinical Applications. |
| Place, publisher, and date of publication | Hoboken : John Wiley & Sons, ©2012 |
| International Standard Book Number | 9783527329946 |
| Record control number | (OCoLC)794134901 |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | http://onlinelibrary.wiley.com/book/10.1002/9783527632909 |
| Public note | Wiley Online Library |
| 938 ## - | |
| -- | EBL - Ebook Library |
| -- | EBLB |
| -- | EBL875950 |
| 938 ## - | |
| -- | YBP Library Services |
| -- | YANK |
| -- | 7607353 |
| 938 ## - | |
| -- | YBP Library Services |
| -- | YANK |
| -- | 7644123 |
| 938 ## - | |
| -- | YBP Library Services |
| -- | YANK |
| -- | 7585093 |
| 994 ## - | |
| -- | 92 |
| -- | DG1 |
No items available.